Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
High-risk Population
100%
Her2neu
100%
Node-negative Breast Cancer
100%
PT1a
100%
Tumor
50%
Node-negative
50%
Breast Cancer
33%
Trastuzumab
33%
Adjuvant Trastuzumab
33%
Disease-free Survival
16%
Independent Prognostic Factor
16%
Prognostic Factors
16%
Breast Cancer Patients
16%
Overall Survival
16%
Human Epidermal Growth Factor Receptor 2 (HER2)
16%
Small Tumor
16%
Clinical Trials
16%
Treatment Effect
16%
Randomized Clinical Trial
16%
Current Guidelines
16%
Submillimeter
16%
Medicine and Dentistry
Breast Cancer
100%
High Risk Population
100%
Tumor
80%
Trastuzumab
80%
Prognostic Factor
40%
Disease Free Survival
20%
Diseases
20%
Retrospective Study
20%
Prospective Study
20%
Clinical Trial
20%
Overall Survival
20%
Epidermal Growth Factor Receptor 2
20%
Gamma Urogastrone
20%
Randomized Clinical Trials
20%
Nursing and Health Professions
Breast Cancer
100%
High Risk Population
100%
Trastuzumab
80%
Clinical Trial
40%
Diseases
20%
Overall Survival
20%
Practice Guideline
20%
Disease Free Survival
20%
Epidermal Growth Factor Receptor 2
20%
Gamma Urogastrone
20%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Trastuzumab
80%
Diseases
20%
Disease Free Survival
20%
Retrospective Study
20%
Prospective Study
20%
Overall Survival
20%
Clinical Trial
20%
Epidermal Growth Factor Receptor 2
20%
Gamma Urogastrone
20%
Randomized Clinical Trial
20%
Mathematics
Cancer Patient
100%
Prospective Study
100%
Retrospective Study
100%
Immunology and Microbiology
High Risk Population
100%
HER2/neu
100%
Trastuzumab
57%
Disease Free Survival
14%
Overall Survival
14%
Gamma Urogastrone
14%